Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future outlook for growth factors

J H Scarffe1

  • 1Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.

Anti-Cancer Drugs
|May 1, 1993
PubMed
Summary

Optimizing growth factor dosage and combinations can improve cancer treatment efficacy and safety. These advancements in bone marrow support will enable higher chemoradiotherapy doses, leading to better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.

British journal of cancer·2005
Same author

Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.

Hematology (Amsterdam, Netherlands)·2003
Same author

Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).

Hematology (Amsterdam, Netherlands)·2003
Same author

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.

Blood·2001
Same author

All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia.

British journal of haematology·2001
Same author

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.

British journal of cancer·2001

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Growth factors are crucial for cellular regulation and development.
  • Current limitations in cancer therapy often relate to dose-limiting toxicities.
  • Advances in supportive care are essential for improving treatment outcomes.

Purpose of the Study:

  • To explore the potential of optimizing growth factor dosage and combinations for enhanced cancer therapy.
  • To investigate the role of growth factors in improving hemopoietic support and reducing toxicities.
  • To re-evaluate chemoradiotherapy approaches in light of improved supportive care.

Main Methods:

  • Optimization of dosage schedules for growth factors.
  • Utilizing combinations of growth factors for hemopoietic support.
  • Employing growth inhibitory cytokines to protect normal tissues.

Main Results:

  • Improved efficacy and safety profiles of growth factors are anticipated with optimized schedules.
  • Combinations of growth factors show promise for treating hematological and non-hematological malignancies.
  • Granulocyte-macrophage colony stimulating factor can enhance neutrophil recovery and mobilize stem cells.

Conclusions:

  • Future improvements in growth factor therapy will enhance cancer treatment.
  • Dose intensification of chemoradiotherapy is feasible with advanced bone marrow support.
  • A reevaluation of chemoradiotherapy strategies is necessary due to progress in supportive care.

Related Experiment Videos